Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2412402 | 1.00 | CYP11B2 (0.36) | CYP11B2DHODHCYP2C19GRIA2KMO | |
| SCHEMBL2414245 | 0.89 | EIF4E (0.38) | DHODHKMOKDM4ECYP3A4ALOX12 | |
| SCHEMBL2414248 | 0.89 | EIF4E (0.38) | DHODHKMOKDM4ECYP3A4ALOX12 | |
| SCHEMBL2412244 | 0.86 | FFAR4 (0.33) | DHODHGSK3BFFAR4 | |
| SCHEMBL2412250 | 0.86 | FFAR4 (0.33) | DHODHGSK3BFFAR4 | |
| SCHEMBL2415464 | 0.84 | PRMT5 (0.36) | DHODHCYP2C19GRIA2BACE1GSK3B | |
| SCHEMBL2415462 | 0.84 | PRMT5 (0.36) | DHODHCYP2C19GRIA2BACE1GSK3B | |
| SCHEMBL2408349 | 0.84 | DYRK1A (0.35) | KMODYRK1A | |
| SCHEMBL2414743 | 0.84 | KMO (0.38) | KMOKDM4ECYP3A4ALOX12TDP1 | |
| SCHEMBL2408347 | 0.84 | DYRK1A (0.35) | KMODYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | CYP11B2 198/4885DHODH 83/4885CYP2C19 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.